BVS.NASDAQBioventus INC

Form 4: Bioventus SVP D'Adamio Reports Equity Award Activity

Sentiment:

Insider Transaction Report

📋All filings for Bioventus INC
🔒Login to Follow

Bioventus Inc.'s SVP & General Counsel, Anthony D'Adamio, reported recent transactions involving Class A Common Stock, Restricted Stock Units, and Stock Options, primarily related to equity compensation and tax obligations.

Summary

  • Anthony D'Adamio, SVP & General Counsel of Bioventus Inc. (BVS), reported changes in his beneficial ownership of company securities.
  • Acquired 8,886 shares of Class A Common Stock on March 13, 2026, through the exercise/conversion of derivative securities at a price of $0.
  • Disposed of 3,861 shares of Class A Common Stock on March 13, 2026, at $8.62 per share, likely for tax withholding purposes.
  • Acquired an additional 8,750 shares of Class A Common Stock on March 13, 2026, through the exercise/conversion of derivative securities at a price of $0.
  • Disposed of 3,802 shares of Class A Common Stock on March 13, 2026, at $8.62 per share, likely for tax withholding purposes.
  • Beneficial ownership of Class A Common Stock after these transactions is 148,042 shares.
  • Received new grants of 35,000 Restricted Stock Units (RSUs) and 40,000 Stock Options (with an exercise price of $9.61) on March 14, 2025.
  • Received new grants of 83,000 RSUs and 92,000 Stock Options (with an exercise price of $8.62) on March 13, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction reflecting standard executive compensation practices. The new equity grants are positive for aligning interests, while tax-related dispositions are expected and neutral.

Positives

  • Grant of new equity awards totaling 118,000 Restricted Stock Units and 132,000 Stock Options indicates continued executive alignment with shareholder interests and retention.
  • The acquisition of Class A Common Stock through RSU conversion at a $0 price represents a direct increase in beneficial ownership without a cash outlay for the shares themselves.

Negatives

  • Disposition of 7,663 shares (3,861 + 3,802) of Class A Common Stock at $8.62 per share for tax withholding purposes, which reduces direct beneficial ownership.

Risks

  • Vesting of Restricted Stock Units and Stock Options is contingent upon the Reporting Person continuing in service through the applicable vesting dates, posing a risk of forfeiture if employment ceases.

Future Outlook

The reporting person is set to acquire additional Class A Common Stock through the vesting of 118,000 Restricted Stock Units and the potential exercise of 132,000 Stock Options over the next four years, contingent on continued service.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units and Stock Options is a standard practice in executive compensation packages across various industries, designed to align management incentives with long-term shareholder value and ensure executive retention. The tax-related dispositions are also a common occurrence when equity awards vest.

Comparison to Industry Standards

  • Equity compensation, including RSUs and stock options with multi-year vesting schedules, is a widely adopted practice among publicly traded companies, particularly in the healthcare and biotechnology sectors where Bioventus operates.
  • This structure is comparable to compensation strategies seen at companies like Stryker Corporation or Zimmer Biomet Holdings, which also utilize performance-based equity awards to incentivize executives and foster long-term commitment. The specific number of shares and exercise prices are company-specific but the mechanism is standard.

Stakeholder Impact

  • Shareholders: Provides transparency into executive compensation and ownership, indicating management's vested interest in the company's long-term performance.
  • Employees: Reflects the company's executive compensation structure, which can influence broader compensation strategies.

Next Steps

  • Continued vesting of 35,000 RSUs and 40,000 Stock Options in four equal annual installments starting March 15, 2025.
  • Continued vesting of 83,000 RSUs and 92,000 Stock Options in four equal annual installments starting March 15, 2026.
  • Potential exercise of stock options before their respective expiration dates of March 14, 2035, and March 13, 2036.

Key Dates

DateDescription
03/14/2023Original grant of 35,545 RSUs began vesting in four approximately equal annual installments.
03/14/2025Acquisition date for 35,000 Restricted Stock Units and 40,000 Stock Options. Vesting for these awards begins on March 15, 2025, in four equal annual installments.
03/15/2025First vesting anniversary for 35,000 RSUs and 40,000 Stock Options.
03/13/2026Transaction date for acquisition of 8,886 and 8,750 Class A Common Stock shares, disposition of 3,861 and 3,802 Class A Common Stock shares, and acquisition of 83,000 Restricted Stock Units and 92,000 Stock Options. Vesting for these new awards begins on March 15, 2026, in four equal annual installments.
03/15/2026First vesting anniversary for 83,000 RSUs and 92,000 Stock Options.
03/17/2026Signature date of the filing.
03/14/2035Expiration date for 40,000 Stock Options granted on March 14, 2025.
03/13/2036Expiration date for 92,000 Stock Options granted on March 13, 2026.

Keywords

Bioventus, BVS, Anthony D'Adamio, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Compensation, SVP General Counsel

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.